Skip to content

Research on the Mechanism of CNN2 regulating glucose Metabolism Reprogramming in Airway Smooth muscle cells through the PI3K/AKT Pathway to promote Allergic Asthma

Research on the Mechanism of CNN2 regulating glucose Metabolism Reprogramming in Airway Smooth muscle cells through the PI3K/AKT Pathway to promote Allergic Asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116147
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic asthma

Interventions

Healthy Group:None

Sponsors

The First Hospital Of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Healthy Group: Age >=18 years old, gender not limited, for those who have participated in the health check-up at our hospital; Be capable of completing this research; No diseases of vital organs such as the heart, lungs, liver and kidneys; There were no abnormalities in the blood routine test and C-reactive protein (CRP). 2. Asthma Group: Meets the asthma diagnostic criteria in the "Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 Edition)"; Age >=18 years old; The clinical data are complete. Be capable of completing this research and all the tests.

Exclusion criteria

Exclusion criteria: Healthy group: Lower respiratory tract infection or related symptoms within two weeks; Currently involved in a drug or any other drug research project. 2. Asthma group: Standardized hormone therapy or cytotoxic drug therapy has already been initiated; In addition to asthma, other chronic inflammatory diseases (inflammatory bowel disease, rheumatoid arthritis) were diagnosed. A history of other serious primary lung diseases, especially those with chronic obstructive pulmonary disease and bronchiectasis; There is a lower respiratory tract infection or related symptoms within two weeks; Currently participating in a drug or any other drug research project; Combined with severe insufficiency of heart, lung, liver and kidney functions; Combined with malignant tumors.

Design outcomes

Primary

MeasureTime frame
Expression of CNN2 mRNA;

Countries

China

Contacts

Public ContactChen Tao

The First Hospital Of Jiaxing

86736710@qq.com+86 573 8251 9936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026